Cross Border Opportunities ... Net Worth

The estimated Net Worth of Cross Border Opportunities ... is at least $1.13 Million dollars as of 5 December 2019. Cross Opportunities owns over 384,130 units of TRACON Pharmaceuticals Inc stock worth over $5,247 and over the last 5 years Cross sold TCON stock worth over $1,125,501.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Cross Opportunities TCON stock SEC Form 4 insiders trading

Cross has made over 1 trades of the TRACON Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Cross sold 384,130 units of TCON stock worth $1,125,501 on 5 December 2019.

The largest trade Cross's ever made was selling 384,130 units of TRACON Pharmaceuticals Inc stock on 5 December 2019 worth over $1,125,501. On average, Cross trades about 384,130 units every 0 days since 2019. As of 5 December 2019 Cross still owns at least 76,048 units of TRACON Pharmaceuticals Inc stock.

You can see the complete history of Cross Opportunities stock trades at the bottom of the page.

Insiders trading at TRACON Pharmaceuticals Inc

Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.

What does TRACON Pharmaceuticals Inc do?

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w

Complete history of Cross Opportunities stock trades at TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc executives and stock owners

TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Charles Theuer,
  President, Chief Executive Officer, Director
• Dr. Charles P. Theuer M.D., Ph.D.,
  CEO, Pres & Director
• Mark Wiggins,
  Chief Business Officer
• Mark C. Wiggins M.B.A.,
  Chief Bus. Officer
• Scott Brown,
  Chief Accounting Officer
• Scott B. Brown CPA, M.S.,
  Chief Financial Officer
• Suzy Benedict,
  Executive Vice President - Regulatory Affairs
• Stephen Worland,
  Independent Director
• J. Rainer Twiford,
  Independent Director
• Martin Mattingly,
  Independent Director
• William LaRue,
  Independent Director
• Saundra Pelletier,
  Director
• Bonne Adams,
  Executive Vice President - Clinical Operations
• Dr. Brenda Marczi Pharm.D., Pharmd Mba,
  Sr. VP of Regulatory Affairs
• Ya Huang,
  Exec. Director of Statistical Programming
• Bonne Adams,
  Exec. VP of Clinical Operations
• Dr. James L. Freddo,
  Chief Medical Officer
• Shahe Garabedian,
  Sr. VP & Head of Quality Assurance
• Ravi Nea Partners 14, L.P.N...,
  
• Peter W.Nea Partners 14, L....,
  
• Scott Dnea Partners 14, L.P...,
  
• Patrick Jnea Partners 14, L...,
  
• David Mnea Partners 14, L.P...,
  
• Anthony A. Jr.Nea Partners ...,
  
• Forestnea Partners 14, L.P....,
  
• Peter Jnea Partners 14, L.P...,
  
• M Jamesnea Partners 14, L.P...,
  
• Capital, Llc Ikarian Health...,
  
• Patricia L Bitar,
  CFO
• Forest Baskett,
  10% owner
• Patrick J Kerins,
  10% owner
• H Casey Logan,
  Chief Business Officer
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• David M Mott,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Enterprise Associates 14, L...,
  
• Tracon Investment Fund Ii, ...,
  
• Paul Edward Walker,
  Director
• Ronald L Shazer,
  Chief Medical Officer
• Krishna Kittu Kolluri,
  10% owner
• Ravi Viswanathan,
  10% owner
• Theodore T Wang,
  Director
• Cross Border Opportunities ...,
  
• Cross Border Opportunities ...,
  
• Harry R Weller,
  10% owner
• Enterprise Associates 14, L...,
  
• Ryan D Drant,
  10% owner
• Super V3 Investment Limited...,
  10% owner
• Management Inc. Opaleye,
  10% owner
• Capital, Llc Ikarian Health...,
  
• Lisa Johnson Pratt,
  Director
• Carol C. Lam,
  Director